trial · primary record
Cilta-cel
Multiple Myeloma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2029-04-06 |
| Primary endpoint | Minimal Residual Disease (MRD)-negative Complete Response (CR) After Cilta-cel Infusion |
| Registry ID | NCT07149857 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:51.075Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07149857
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cilta-cel · compound